NavidHeyrani

Associate

(T) + 1.949.553.7579

Navid Heyrani's practice focuses on public and private M&A (both domestic and cross-border), corporate governance, and general corporate and securities matters.

Navid represents clients from a broad range of industries, including biopharmaceutical, medical device, pharmaceutical, technology, energy, telecommunications, and retail. Representative clients include Abbott Laboratories, Advantage Solutions, Ambry Genetics, Astellas Pharma US, the Internet Corporation for Assigned Names and Numbers (ICANN), Linear Technologies, Silver Chef Limited, Social Finance, Sumitomo Corporation, TDK Corporation, and Terumo Corporation.

Recent representations include Linear Technology's $14.8 billion sale to Analog Devices; TDK Corporation's $1.3 billion acquisition of InvenSense; Ambry Genetics' $1.0 billion sale to Konica Minolta; Advantage Solution's acquisitions of The Data Council, Quiverr Collective, and Upshot, Inc.; and ICANN in connection with the successful completion of the transition of the Internet Assigned Numbers Authority functions from the U.S. National Telecommunications and Information Administration to ICANN.

Experience

  • Misonix acquires Solsys Medical, LLCJones Day advised Misonix, Inc. in its acquisition of Solsys Medical, LLC, a privately held regenerative medical company, in an all-stock transaction valued at approximately $109 million.
  • Western Digital acquires Kazan NetworksJones Day advised Western Digital Corporation (NASDAQ:WDC) in its acquisition of Kazan Networks Corp., a provider of industry leading NVMe™-over-Fabric (NVMe-oF) ASIC and adapter products for next-generation data center architectures.
  • Evidera acquires MedimixJones Day advised Evidera, a business unit of Pharmaceutical Product Development, LLC, in its acquisition of Medimix International, a global technology company providing real-world evidence (RWE) insights and information to the pharmaceutical, diagnostic, and medical device industries.
  • Lam Research completes $2.5 billion public offering of Senior NotesJones Day advised Lam Research Corporation, a global supplier of wafer fabrication equipment and services to the worldwide semiconductor industry, in connection with its underwritten public offering of $2.5 billion of Senior Notes, consisting of $750 million of 3.750% Senior Notes due 2026, $1.0 billion of 4.000% Senior Notes due 2029, and $750 million of 4.875% Senior Notes due 2049.
  • Advantage Solutions acquires Jun GroupJones Day advised Advantage Solutions on its acquisition of Jun Group, an industry-leading mobile video advertising company.
  • Syndicate of financial institutions provide $500 million credit facility to California developerJones Day represented a syndicate of financial institutions in connection with a $500 million unsecured credit facility, comprised of a $350 million revolving facility and $150 million term loan, provided to a California developer.
  • Social Finance acts as intermediary for Ventura County Project to Support ReentryJones Day represented Social Finance, Inc. in its role as intermediary for the Ventura County Project to Support Reentry, a collaborative pay for success project between Ventura County, Interface Children & Family Services, and Social Finance.
  • Ambry Genetics sold to joint venture formed by Konica Minolta and Innovation Network for up to $1.0 billionJones Day advised Ambry Genetics Corporation, a leading genetic testing corporation, in its sale to a newly formed joint venture between Konica Minolta, Inc. and Innovation Network Corporation of Japan for up to $1.0 billion (including earnouts).
  • Advantage Solutions acquires The Data CouncilJones Day advised Advantage Solutions in the acquisition of The Data Council, the leading provider of verified and standardized product data and images.
  • Advantage Solutions acquires QuiverrJones Day advised Advantage Solutions in its acquisition of Quiverr Collective, LLC.
  • TDK acquires InvenSense for $1.3 billionJones Day advised TDK Corporation in its $1.3 billion acquisition of InvenSense, Inc.
  • Linear Technology acquired by Analog Devices for $14.8 billionJones Day advised Linear Technology Corporation on its sale to Analog Devices, Inc.
  • ICANN advised in connection with governance reform and transition of IANA functionsJones Day advised Internet Corporation for Assigned Names and Numbers (ICANN) in connection with the successful completion of the transition of the Internet Assigned Numbers Authority (IANA) functions from the U.S. National Telecommunications and Information Administration to ICANN.
  • Sumitomo Dainippon Pharma acquires Tolero Pharmaceuticals, Inc.Jones Day advised Sumitomo Dainippon Pharma Co. Ltd., a leading pharmaceutical company based in Japan, in its acquisition of Tolero Pharmaceuticals, Inc.
  • Lam Research attempts merger with KLA-TencorJones Day represented Lam Research Corporation in its proposed acquisition of all outstanding shares of KLA-Tencor Corporation in a cash and stock transaction that placed an equity value on KLA-Tencor of approximately $10.6 billion based on its closing stock price on October 20, 2015.
  • Astellas sells U.S. manufacturing subsidiary to AvaraJones Day advised Astellas Pharma Inc. in the transfer of its wholly owned manufacturing subsidiary Astellas Pharma Technologies, Inc. to Avara Norman Pharmaceutical Services, Inc.
  • Diebold sells North America electronic security business to Securitas for $350 millionJones Day advised Diebold, Incorporated in the $350 million sale of its North America-based electronic security business to Securitas AB to accelerate its transformation and better position the company to pursue growth opportunities in the dynamic self-service industry.
  • Atmel receives unsolicited superior proposal and terminates definitive agreement to be acquired by Dialog for $4.6 billionJones Day represented Atmel Corporation in connection with its definitive agreement to be acquired by UK-based Dialog Semiconductor plc in a cash and stock transaction for $4.6 billion.
  • BioMarin acquires global rights to Phenylketonuria (PKU) franchise from Merck Serono for $588.8 millionJones Day advised BioMarin Pharmaceutical Inc. in connection with its €525 million ($588.8 million) acquisition of the global rights to Kuvan® (sapropterin dihydrochloride) and pegvaliase from Merck Serono.
  • Abbott purchases option to acquire Cephea Valve TechnologiesJones Day advised Abbott Laboratories in the providing of capital and securing of an option to purchase Cephea Valve Technologies, a private company developing a catheter-based mitral valve replacement therapy.
  • We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.